AbbVie's Decnupaz Secures FDA Approval for Rare Blood Cancer

AbbVie's Decnupaz Secures FDA Approval for Rare Blood Cancer

The US FDA has approved AbbVie's antibody-drug conjugate, Decnupaz (pivekimab sunirine-pvzy), for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This marks AbbVie's first ADC entry in the blood cancer space and the first ADC approval for this ultra-rare indication. The regulatory clearance strengthens AbbVie's oncology pipeline and opens a commercial niche in a disease affecting roughly 500 to 1,000 patients annually in the US.

Key Takeaways

• AbbVie's Decnupaz (pivekimab sunirine-pvzy) receives US FDA approval for blastic plasmacytoid dendritic cell neoplasm (BPDCN).
• Decnupaz is the first ADC approved for BPDCN, an ultra-rare and aggressive blood cancer.
• The approval is based on the Phase I/II CADENZA trial, demonstrating significant remission rates.
• A boxed warning for hepatotoxicity is included due to serious liver risks.
• This approval strengthens AbbVie's ADC portfolio and competitive position in rare hematologic malignancies.

FDA Approves Decnupaz for Blastic Plasmacytoid Dendritic Cell Neoplasm

The US Food and Drug Administration (FDA) has approved AbbVie's antibody-drug conjugate (ADC), pivekimab sunirine-pvzy, marketed as Decnupaz. The approval covers adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare and aggressive form of blood cancer. Decnupaz is the first ADC to receive approval for this specific indication, marking a significant milestone for AbbVie in the hematologic oncology space.

The regulatory decision was supported by data from the Phase I/II CADENZA trial (NCT03386513), which showed notable efficacy in both treatment-naive and relapsed/refractory BPDCN patient populations. The drug targets the CD123 biomarker present on BPDCN cells and delivers a cytotoxic indolinobenzodiazepine payload that damages DNA upon internalization, destroying the malignant cell.

BPDCN is a rare form of leukemia that affects the bone, skin, and lymph nodes. The disease manifests primarily as skin lesions, which vary in shape, size, and color. While the initial presentations may seem harmless, BPDCN is aggressive and can quickly spread throughout the body, often causing blood-related complications such as anemia and thrombocytopenia.

Read the Reuters report on the FDA approval

Clinical Efficacy and Safety Profile

The FDA's approval of Decnupaz was based on results from the Phase I/II CADENZA trial, which enrolled 33 treatment-naive patients with BPDCN and 51 patients with relapsed or refractory BPDCN. In treatment-naive patients, Decnupaz achieved a composite complete remission (CR/CRc) rate of 69.7% at a median follow-up of 21.5 months. For patients with relapsed or refractory BPDCN, the CR/CRc rate was 15.7% at a median follow-up of 24.1 months.

While demonstrating clinical benefit, the drug carries a boxed warning for hepatotoxicity, highlighting the risk of serious and potentially fatal liver problems, including hepatic veno-occlusive disease, a condition in which blood flow in the liver is blocked. The FDA flagged the risk of blockages in the small veins in the liver, which could become life-threatening and lead to death.

Other common side effects reported include edema, fatigue, musculoskeletal pain, hemorrhage, nausea, and diarrhea, all of which occurred in at least 20% of treated patients.

Market Landscape and Competitive Implications

The approval of Decnupaz positions AbbVie as a leader in the treatment of BPDCN, an area with limited therapeutic options. As the first ADC for this indication, Decnupaz offers a novel mechanism of action. Investors and analysts will monitor AbbVie's stock performance (ABBV) following this approval, assessing its commercial potential in this niche market.

The success of Decnupaz also validates AbbVie's broader ADC strategy and may influence future pipeline developments and potential partnerships in the oncology space. The company is also investigating Decnupaz for acute myeloid leukemia (AML), for which the asset is in mid-stage development.

AbbVie Inc, the U.S.-based biopharmaceutical group listed on the NYSE under the ticker ABBV, starts the new week with investors still digesting this fresh U.S. regulatory milestone.

Frequently Asked Questions

Related profiles

• AbbVie
• AstraZeneca